BMC Health reports first commercial implants of urethral compression device

BMC Health says it has completed the first commercial implantations of its UNIQ Implants urethral compression device for men with stress urinary incontinence. The early cases in Costa Rica mark a key step as the company continues follow-up, prepares regulatory submissions in Europe and the United States, and says the device is designed to simplify surgery by avoiding urethral dissection.

Why it matters: - Male stress urinary incontinence is often treated with technically demanding surgery. - BMC Health’s device is designed to remove the need for urethral dissection, which could make the procedure shorter, less invasive and easier to reproduce. - The first commercial implantations are a real-world test of whether that design can translate into routine clinical use.

What happened: - BMC Health announced the first implantations of the commercial version of its UNIQ Implants® Urethral Compression Device. - The first two patients were treated at the Sulàyöm Global Learning Center in Alajuela, Costa Rica. - Professor Bruno Machado, MD, from AdventHealth, Florida, and Dr. Luis Esquivel, from Costa Rica, performed the procedures during a clinical follow-up series. - The patients received commercial units of the device.

The details: - The UNIQ Implants® Urethral Compression Device is intended for men with stress urinary incontinence. - The device restores continence through controlled compression of the urethra. - The design avoids dissection of the urethra. - Conventional artificial urinary sphincter surgery includes urethral dissection, a step many surgeons prefer to avoid because it makes the procedure more technically demanding. - BMC Health says the follow-up will assess safety, feasibility and patient-reported outcomes. - Reporting is planned through 24 months. - Enrollment under the follow-up protocol will continue. - The UNIQ Implants® Urethral Compression Device is registered in Costa Rica. - The device is not approved or cleared for sale in the United States or the European Union. - BMC Health is a medical device company founded in 2022. - The company develops implants for male urological and sexual health, including stress urinary incontinence and erectile dysfunction. - BMC Health manufactures through its subsidiary at an ISO 13485/MDSAP-certified facility in the Coyol Free Zone in Alajuela, Costa Rica. - More information is available on the company’s website. - The company also shared updates on LinkedIn and Instagram.

Between the lines: - The first commercial use suggests BMC Health is moving beyond development toward early market validation. - The study design still matters because the company is tracking safety and feasibility over two years, which means broad performance claims remain unproven. - Regulatory work in Europe and the United States signals the next major hurdle for wider adoption. - The quoted surgeons framed the device as potentially safer and more reproducible, but those are forward-looking views rather than confirmed outcomes.

What's next: - BMC Health will keep enrolling patients under the follow-up protocol. - The company is advancing regulatory submissions in Europe and the United States. - Longer-term results through 24 months will help show whether the device can deliver on its intended benefits.

The bottom line: - BMC Health has crossed from development into first commercial use, but the device still needs follow-up data and regulatory clearance before it can scale beyond Costa Rica.